Progressive alliance advances science through patient-powered research - Insights
Tying together the expertise and curiosity of Mayo Clinic autoimmune neurology researchers with eager patients who have rare disease and are looking for answers, the innovative collaboration benefits both patients affected by MOGAD and...
COVID-19: The pandemic that's forever changed laboratory testing - Insights
Since March 2020, the COVID-19 pandemic has had a lasting impact on the lives of millions of people around the world, including the many brave health care workers who risked their own health to provide lifesaving care to those infected by...
New AI-augmented test refines kidney stone analysis - Insights
Since March 2019, Paul Jannetto, Ph.D., director of the Metals Laboratory at Mayo Clinic, along with his colleagues across the enterprise and his laboratory staff, have developed, validated, and implemented an artificial intelligence...
Optional MFA for Mayo Clinic Laboratories applications coming soon - Insights
Mayo Clinic Laboratories is committed to security and to protecting your information. As part of this commitment, we will implement an optional two-step login process for Mayo Clinic Laboratories applications called Multi-Factor...
Novel biomarkers added to movement disorders profile - Insights
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
Seasonal Outlook of Respiratory Viruses: Matthew Binnicker, Ph.D. - Insights
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo...
Summertime Pathogens: Bill Morice, M.D., Ph.D. - Insights
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They...
Next-generation sequencing lung cancer panel identifies more genetic abnormalities - Insights
Mayo Clinic Laboratories’ new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG) provides more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.
Facebook Email or phone Password...
Facebook Email or phone Password...